M4 muscarinic receptor Inhibitors
1 drugsAbout M4 muscarinic receptor
The M4 muscarinic receptor is a G protein-coupled receptor that binds acetylcholine, modulating central and peripheral nervous system activity. It plays diverse roles in neurotransmission and cellular signaling pathways.
Currently, there is no genetic evidence directly linking the M4 muscarinic receptor to specific diseases, limiting confidence in target validation.
One FDA-approved drug, darifenacin, targets muscarinic receptors and was first approved in 2017. It is a small molecule drug marketed by MACLEODS PHARMS LTD.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Untreated Follicular Lymphoma with only 1 trials.
Top M4 muscarinic receptor Drugs
MACLEODS PHARMS LTD is the only company with an approved drug targeting muscarinic receptors.
Low competitive intensity may present an opportunity for new entrants, but also indicates potential challenges in market viability.
M4 muscarinic receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets M4 muscarinic receptor, using small molecule modality.
Explore opportunities for novel modalities like antibodies or peptides to differentiate from existing treatments.
M4 muscarinic receptor Clinical Trials 8 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 1 | 1 | 0% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
M4 muscarinic receptor Drug Approval Timeline (2017 - 2017)
Darifenacin was first approved in 2017 and remains the most recent approval.
The lack of recent approvals suggests a potentially saturated market or challenges in developing new M4-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 19 clinical trials targeting M4 muscarinic receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities